The Royal Commission for AlUla Launches Its Second Winter at Tantora Festival of Culture, Heritage and Celebration in Saudi Arabia
The second Winter at Tantora Festival in AlUla in North West Saudi Arabia starts today – a three-month celebration that will showcase the very best in international music, art and culture connecting East and West as the AlUla county has done for thousands of years.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191219005781/en/
Winter at Tantora: Experience AlUla (Photo : AETOSWire)
It comes just months after Saudi Arabia introduced tourist visas to citizens from 49 countries making the Kingdom more accessible than ever with the UNESCO World Heritage site at Hegra in AlUla among those featured in a global marketing campaign.
The festival is part of the Cultural Manifesto that was launched by the festival organisers, the Royal Commission for AlUla, in Paris in October as part of a long-term strategy to transform the region and open the region as a global living museum and place of culture, heritage and the arts.
Winter at Tantora will cover 12 weekends from 19th December and host a wide range of events from the world-famous Dakar Rally; international ballooning festival; the world’s second longest endurance horse race; the world’s first desert polo tournament and welcome pop-up restaurants from globally renowned restaurants.
The spectacular mirrored wall Maraya Theatre with its 500-seat capacity and operatic sound quality will be home throughout the festival to some of the world’s leading performers who range from Omar Khairat to Andrea Bocelli.
Festival visitors will also be able to meet and engage with young members of the AlUla community who are benefitting from a diverse range of training programmes in hospitality; culture; nature and the environment and studying overseas including 24 men and women at the FERRANDI Paris culinary institute in Paris.
These young chefs will work alongside Michelin-starred experts during the festival creating world-class cuisine that will incorporate local ingredients from the fertile AlUla valley and blending traditional recipes with modern cuisine.
RCU CEO Amr AlMadani says: “Festival visitors will be given a unique opportunity to visit and experience one of the world’s undiscovered places and its spectacular heritage sites before we reopen them to the world in October 2020.
“They will get a tantalising glimpse of a place that been a cultural crossroads for thousands of years and the chance to see it from the serenity of a hot air balloon; the adrenaline of soaring over the desert and mountains in an open seater biplane or exploring hidden canyons in traditional vintage Land Rovers.”
The Royal Commission for AlUla has also completed major infrastructure work at AlUla airport – increasing capacity fourfold to 400,000 visitors a year and upgrading local mountain resorts to enhance the visitor experience.
AlUla will be a worldwide destination for those seeking a unique experience of the full meaning and context of landscape – an experience that integrates the natural and cultural heritage as one living environment. By safeguarding our precious landscapes and cultural heritage this open-air museum will be the Kingdom’s gift to the world creating remarkable and lasting memories.
‘Authentic AlUla’, the opening weekend, is a celebration rooted in AlUla, to mark the start of the winter planting season at the iconic Tantora sundial from which the festival is named. It is the first of 12 specially themed weekends.
Notes to editors
To find out more about the Winter at Tantora festival and details of packages and the entertainment and cultural programmes, log on to www.experiencealula.com
To find out more about how the Royal Commission for AlUla is working with the community to develop a world-class tourism destination, log on to www.rcu.gov.sa
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191219005781/en/
Contact information
RCU Public Relations team
The head of PR at RCU
Antony Newton
PublicRelations@rcu.gov.sa
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Curing the Incurable with ‘Biological Age Zero’ Cells: Clonell™ Launches the Ultimate Regenerative Medicine Platform5.1.2026 15:00:00 EET | Press release
Clonell Therapeutics, Inc., a leading biotechnology company dedicated to curing intractable and incurable diseases, announced today the official launch of the world's first 'Patient-Specific Embryonic Stem Cell (Somatic Cell Nuclear Transfer-derived Embryonic Stem Cell, hereinafter SCNT-ESC)' therapy platform based on Somatic Cell Nuclear Transfer (SCNT) technology. Concurrently, the company has initiated its innovative 'Patient-Initiated Clinical Trial™' to apply this breakthrough technology directly to patients. This platform launch is evaluated as presenting the true 'Gold Standard' in regenerative medicine by perfectly resolving the inherent challenges—such as immune rejection, incomplete reprogramming, and the inheritance of aging—that have been cited as limitations of existing stem cell therapies. Clonell's SCNT technology establishes a patient-specific embryonic stem cell line by transferring the nucleus of a patient's somatic cell into a healthy enucleated oocyte. This process
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi ® /Minjuvi ® ) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 14:30:00 EET | Press release
Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years of age, or age-adjusted IPI (aaIPI) of two to three (2-3) for patients ≤60 years of age. The trial met its primary endpoint of progression-free survival (PFS) by investigator assessment (Hazard Ratio 0.75 [0.59,0.96]; p-value 0.019), according to Lugano 2014 criteria. The trial also met its key secondary endpoint of event-free survival (EFS) by investigator assessment. No new safety signals were observed. “The frontMIND stud
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 14:30:00 EET | Press release
Cybin Inc. (the “Company”) doing business as Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (“Helus Pharma”), a clinical stage pharmaceutical company committed to helping minds heal by developing NSAs, today announced that the Company will operate under the business name Helus Pharma (pronounced “Heal-Us”) and trade on Nasdaq with ticker symbol HELP. “Our new business name more accurately describes our compounds and reflects our anticipated transformation from a global clinical stage discovery and development company to a commercial-ready pharmaceutical company, with our two lead candidates HLP003 and HLP004,” said Eric So, interim chief executive officer of the Company. “Over the past several years, we have advanced our pipeline portfolio of differentiated, proprietary NSA drug candidates, which includes over 350 filed patents with more than 100 already granted. We are approaching the commercialization of HLP003 with strong clinical data and significant market potential, subject to the
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)5.1.2026 14:00:00 EET | Press release
Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell production to control hematocrit levels in patients with PV. “This is an important milestone toward our goal of addressing critical gaps that patients living with polycythemia vera face today,” said Teresa Bitetti, President, Global Oncology Business Unit, Takeda. “The comprehensive VERIFY study data underscore rusfertide’s strong clinical profile and potential to provide sustained hematocrit control while reducing phlebotomy and symptom burden. Our collaboration with Protagonist exemplifies how partnerships can advance innovative science, with a focus on m
SBC Medical Accelerates Global Expansion with Strategic Investment and Alliance with a Leading U.S. MedSpa Platform OrangeTwist as Part of Broader Growth Strategy5.1.2026 14:00:00 EET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the completion of a strategic minority equity investment and the establishment of a structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain, alongside its longstanding institutional shareholders, Hildred Capital and Athyrium Capital. This transaction marks SBC Medical’s formal entry into the United States—a key global market for medical aesthetics—and represents a major milestone in the Company’s broader global expansion strategy. For more details, click here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210926005/en/ OrangeTwist Supporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom